Abstract | BACKGROUND: OBJECTIVE: METHODS: All patients received budesonide aqueous nasal spray or placebo for 2 weeks. The study was double-blind, parallel group, placebo controlled, and randomized. Nasal lavage was performed in all patients before and after treatment. A panel of cytokines, including interleukin 4 (IL-4), IL-5, and IL-6, was measured by immunoassay on fluids recovered from nasal lavage. Total symptom score (including rhinorrhea, nasal itching, sneezing, and nasal obstruction) was evaluated before and after treatment. RESULTS: Twenty patients with perennial allergic rhinitis were evaluated (13 men and 7 women; mean age, 24.7 years). Budesonide aqueous nasal spray treatment showed a significant decrease of IL-4 (P = .007), IL-5 (P = .04), and IL-6 levels (P = .009). Budesonide aqueous nasal spray treatment also induced significant symptom relief (P = .006). Placebo treatment did not significantly affect the evaluated parameters. CONCLUSIONS:
|
Authors | Giorgio Ciprandi, Maria Angela Tosca, Ignazio Cirillo, Andrea Vizzaccaro |
Journal | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
(Ann Allergy Asthma Immunol)
Vol. 91
Issue 5
Pg. 467-71
(Nov 2003)
ISSN: 1081-1206 [Print] United States |
PMID | 14692430
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents
- Cytokines
- Interleukin-5
- Interleukin-4
- Budesonide
|
Topics |
- Adolescent
- Adult
- Anti-Inflammatory Agents
(therapeutic use)
- Budesonide
(therapeutic use)
- Cytokines
(drug effects, metabolism)
- Double-Blind Method
- Female
- Humans
- Interleukin-4
(metabolism)
- Interleukin-5
(metabolism)
- Male
- Rhinitis, Allergic, Perennial
(drug therapy, metabolism)
- Seasons
- Severity of Illness Index
- Statistics as Topic
- Treatment Outcome
|